HAHend M. Alotaibi

Hend M. Alotaibi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hend M. Alotaibi has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risankizumab in Psoriasis: Real-World Effectiveness, Safety, and Clinical Outcomes

    by Maha Alkofide, Abdulaziz Madani, Sarah Alsukait, Hend Alotaibi, Huda Salim Almaqbali, Naif Ahmed Alshehri, Maee Barakeh, Bandar Ahmed Alharbi, Khalid Nabil Nagshabandi

    Background: Risankizumab (anti–IL-23 p19) is an established therapy for moderate-to-severe psoriasis, with strong trial efficacy and growing real-world evidence. However, long-duration outcomes and treatment-spacing patterns from the Gulf region remain limited. Objective: To evaluate long-term effectiveness, safety, and treatment patterns—including extended-interval dosing—of Risankizumab in a real-world tertiary center. Methods: Single-center retrospective cohort of adults treated with Risankizumab between January 2020 and January 2025. Primary outcome: Psoriasis Area and Severity Index (PASI) 100 on last visit. Secondary outcomes: changes in Psoriasis Area and Severity Index (PASI), body surface area (BSA), and Dermatology Life Quality Index (DLQI) and Nail Psoriasis Severity Index (NAPSI); adverse events; treatment persistence and dosing intervals. Non-parametric tests were used; predictors of PASI 100 were explored with multivariable logistic regression. Results: We included 144 patients (mean age 39.3± 14.9 years; 55.6% male; mean BMI 29.0± 6.5). At last visit, 61.1% achieved PASI 100. Mean scores improved from baseline to last visit: PASI 7.24→ 0.34, BSA 9.81%→ 0.26%, DLQI 7.64→ 0.68, NAPSI 9.56→ 2.94 (all p< 0.001). Adverse events were infrequent (3.5%), all mild; no major adverse cardiovascular events or deaths occurred. A single case of lung cancer was reported and considered unlikely to be treatment related. A quarter of patients transitioned to extended intervals (most commonly every 4– 6 months), with the majority maintaining disease control and relapse occurring infrequently and only after ≥ 6 months. Longer treatment duration and maintenance of standard dosing frequency were associated with achieving PASI 100, while positive family history was associated with lower odds of complete clearance. Conclusion: In routine practice, Risankizumab achieved high complete-clearance rates with excellent tolerability over ~31 months’ mean exposure. Extended-interval dosing was feasible in selected stable responders. These findings align with trial durability and regional registry signals and support individualized long-term strategies.

  • Open Access

    Psychological Wellbeing of Patients with Chronic Spontaneous Urticaria and Its Relation to Their Overall Health-Related Quality of Life

    by Maha Saja, Raneem Alhoqail, Renad Alduwayan, Lamia Alsubaie, Layan Alhelal, Fay Alluhaydan, Hend Alotaibi

    Chronic spontaneous urticaria (CSU) is a chronic skin disease characterized by the appearance of wheals with or without angioedema for more than 6 weeks. Its troublesome symptomatology, recurrent nature, and long-term treatment can be physically, psychologically, and economically challenging to patients adversely affecting their psychological wellbeing and health-related quality of life (HRQoL). This study aimed at (i) measuring the level of anxiety and depression in patients with CSU, (ii) evaluating their HRQoL, and (iii) assessing the relationship between psychological wellbeing and HRQoL in those patients. In this cross-sectional study, patients with CSU (n=114) were recruited by convenience sampling from the dermatology clinic at King Saud University Medical City (KSUMC) between October 2022 and April 2024. Four datasets were collected from each patient: (i) Sociodemographic, disease-, and medication-related characteristics, (ii) anxiety level using the General Anxiety Disorder 7-Item (GAD-7) Scale, (iii) depression level via the 9-item Patient Health Questionnaire (PHQ-9), and (iv) HRQoL using the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). The mean age was 42 (SD: 12.5) with 90.4% being females. The majority had mild-to-moderate disease activity. Around 8% reported concomitant inducible urticaria while 53.5% reported angioedema. The prevalence of patients with CSU at risk of either Generalized Anxiety Disorder (GAD) or Major Depressive Disorder (MDD) was around 28% for each. Mean CU-Q2oL score was 35.3 (SD: 23.4). Several factors were shown to be significantly associated with higher anxiety and depression levels as well as lower HRQoL including, disease activity, presence of angioedema, drug allergy, and the use of sedative antihistamines. Multivariable regression analysis identified high anxiety and depression levels as significant independent predictors of lower HRQoL in patients with CSU. Clinically significant anxiety and depression are prevalent among patients with CSU and are linked to lower HRQoL in those patients.

  • Open Access

    Impact of Bariatric Surgery on Quality of Life and Psychological Well-Being Among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study

    by Sarah Alsukait, Hend Alotaibi, Maha Alkofide, Abdulaziz Madani, Basel Almalki, Naif Alshehri, Reem Alsergani, Hadeel Alzahrani

    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with obesity, substantial psychosocial burden, and symptom-related discomfort. Bariatric surgery achieves sustained weight loss and may improve psychological well-being, yet its effect on HS-related quality of life and symptom burden remains uncertain. To evaluate the association of bariatric surgery with psychological well-being, quality of life, and pain among patients with HS using validated patient-reported outcome measures. We conducted a analytical cross-sectional study between January 2024 and January 2025 at King Saud University Medical City, Riyadh, Saudi Arabia. Consecutive adult patients with HS were enrolled after informed consent. Disease severity was assessed using Hurley staging. Participants completed the Dermatology Life Quality Index (DLQI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), and a visual analog scale (VAS) for pain. Outcomes were compared between patients with and without prior bariatric surgery using independent t-tests and general linear models adjusted for age, sex, Hurley stage, and diagnostic delay. Among 135 participants, 77 (57.0%) were female and 15 (11.1%) had undergone bariatric surgery. Patients with prior bariatric surgery had lower mean DLQI (8.13 vs 8.62), PHQ-9 (5.73 vs 7.50), GAD-7 (5.87 vs 6.31), and VAS pain (2.80 vs 3.69) scores than those without surgery; however, these differences were not statistically significant after adjustment (all p>0.05). DLQI correlated positively with PHQ-9 (r=0.334) and GAD-7 (r=0.323), while pain correlated moderately with DLQI (r=0.546; p<0.001). In this cross-sectional sample, prior bariatric surgery was not associated with statistically significant differences in quality of life, depressive symptoms, anxiety symptoms, or pain after adjustment. However, patients with prior bariatric surgery showed consistently lower mean scores across these outcomes. Larger prospective longitudinal studies with more detailed surgical subgroup data are needed to determine the magnitude and durability of any potential benefit.

  • Open Access

    Multidisciplinary Management of Paraneoplastic Pemphigus Associated with B-Cell Lymphoma: A Case Report

    by Loulwah Alothman, Azizah Bin Mubayrik, Nuha Alfurayh, Sara Aldosary, Hend M Alotaibi, Abdulmajeed Alajlan

    Paraneoplastic pemphigus is a rare life-threatening blistering autoimmune mucocutaneous disease associated with various neoplasms. In contrast to the skin, mucosal lesions are refractory and requires considerable healing time, heals far more slowly. A multidisciplinary approach may provide a comprehensive management and a better prognosis. A sixty-one-year-old male patient presented to the ER department in June 2020 complaining of severe inflammation of the left eye along with scaly erythematous skin eruptions affecting the hands, trunk, and feet. Subungual hematoma was also observed. Clinical examination revealed extensive oral ulceration involving the dorsum and ventral surface of the tongue, buccal mucosa, labial mucosa, and hematic crusts were noticed on the lips. The patient was admitted for panophthalmitis secondary to a perforated corneal ulcer. Dermatological investigations were requested in addition to extensive baseline studies to rule out malignancies. The patient had a retroperitoneal lesion and underwent CT guided biopsy. Result was suggestive of low-grade B cell non-Hodgkin’s lymphoma. He was treated by the haematology-oncology, dermatology and oral medicine teams. Paraneoplastic pemphigus (PP) is a fatal autoimmune blistering disease associated with underlying malignancy. A multidisciplinary approach to achieve early diagnosis and better management is essential to improve the quality of life of such patients despite their poor prognosis. Paraneoplastic pemphigus is a rare disease associated with mucocutaneous ulcerations and various malignancies, including lymphoproliferative neoplasms. As demonstrated in the current case, multidisciplinary assessment and management have proven to be effective in managing the patient. Physicians and dentists should make their best effort to work collaboratively to manage patients and minimize patient distress and improve life quality and prognosis.

  • Open Access

    Adverse Cutaneous Reactions Following COVID-19 Vaccination Among Patients with Pre-Existing Urticaria: A Cross-Sectional Study at a Tertiary Care Center in Saudi Arabia

    by Ashwag Asiri, Hend M Alotaibi, Nouf Ali Alotaibi, Alfahdah Abdullah Alsaleem

    Purpose: To investigate the incidence, characteristics, and associated factors of cutaneous adverse reactions to COVID-19 vaccines among adult patients with pre-existing urticaria in Saudi Arabia. Patients and Methods: A cross-sectional study enrolled 190 adult patients (≥ 18 years) with urticaria attending allergy/dermatology clinics at King Khalid University Hospital, Riyadh (November 2021–April 2022). Data on demographics, urticaria characteristics, vaccination status, cutaneous reactions, and comorbidities were collected via questionnaire. Statistical analyses included descriptive statistics, Chi-square/Fisher exact tests, Cochran’s test, and binary logistic regression. Results: Participants were predominantly female (87.4%), with chronic spontaneous urticaria (97.9%); 78.9% used regular antihistamines. Reactions occurred after dose 1 (22.7%), dose 2 (26.2%), and dose 3 (31.0%). Among symptomatic individuals, onset was typically < 24h, resolving in 1– 3 days for ~50%. Common reactions included injection site reactions (13.1– 16.3%), pruritus (7.8– 10.5%), and urticaria exacerbation (3.9– 9.1%). Urticaria exacerbation decreased significantly after dose 3 (p=0.030). Regular antihistamine use was associated with fewer reactions after dose 1 (adjusted OR 0.4, p=0.028). Female gender, asthma/atopy, and autoimmune disease were associated with specific reactions. Adjusted vaccine type showed no significant association. Conclusion: Cutaneous reactions post-COVID-19 vaccination in urticaria patients are relatively common but generally mild and transient. Decreasing urticaria exacerbations after dose 3 is reassuring. Regular antihistamine use may offer some protection, particularly after the first dose. Findings support vaccine safety and aid patient counseling. Plain Language Summary: Understanding how COVID-19 vaccines affect people with existing skin allergies is 41 crucial for public health. Our study focused on patients with urticaria (chronic hives) 42 who received COVID-19 vaccines. We found that while many patients experienced 43 mild skin reactions after vaccination, these reactions were generally temporary and 44 manageable. Most reactions occurred within 24 hours of vaccination and resolved within 45 a few days. Importantly, patients who regularly took antihistamine medications were 46 less likely to develop reactions. This research provides reassurance that COVID-19 47 vaccines can be safely administered to people with pre-existing urticaria, although some 48 may experience temporary symptoms. These findings help both healthcare providers 49 and patients make informed decisions about vaccination.


  • Illness perception, psychological distress, and quality of life in patients with alopecia: a cross-sectional study from Riyadh, Saudi Arabia

    by Hend M. Alotaibi, Reem Bin Idris, Ahmed H. Alajlan, Abdulaziz A. Alghufaili, Maee Barakeh, Shaden A. Alobaid, Norah K. Algarzae

    Background Alopecia, a condition marked by hair loss, includes androgenic alopecia (AGA), alopecia areata (AA), telogen effluvium (TE), and scarring alopecia, each with a unique pathophysiology that profoundly impacts psychological well-being, self-image, and quality of life (QoL), leading to anxiety and depression. Understanding illness perception and its connection to QoL and mental health in comorbid Saudi patients, especially in patients with the simultaneous presence of more than two medical conditions, remains limited. We aimed to assess Saudi patients’ perception of different types of alopecia and explore the relationship between illness perception, QoL, psychological factors, and comorbidities. Methods: A cross-sectional survey was conducted at King Khalid University Hospital, Riyadh, from December 2023 to March 2024. Ninety-nine adults with confirmed alopecia diagnoses completed validated questionnaires, including the Brief Illness Perception Questionnaire (BIPQ), the Dermatology Life Quality Index (DLQI), the Patient Depression Questionnaire (PHQ-9), and the Generalized Anxiety Disorder Scale (GAD-7). Statistical analysis included regression models to determine predictors of QoL impairment. Results: the most common type of alopecia was AGA (47.5%), followed by AA (30.3%), scarring alopecia (16.2%), and TE (6.1%). Median scores for BIPQ and DLQI were 49.0 and 6.0, respectively, indicating moderate illness perception and QoL impact. Anxiety and depression levels were generally mild, though scarring alopecia patients reported higher emotional distress. Negative illness perception was strongly associated with reduced QoL and higher anxiety and depression scores. Factors such as illness perception, anxiety, and mental health conditions were significant predictors of QoL impairment. Conclusion: Our findings underscore the psychological impact of alopecia and highlight the importance of addressing both physical symptoms and mental health in patient care. Thus, Targeted interventions focusing on illness perception and emotional well-being are crucial for improving outcomes.


  • Open Access

    Systematic review, methodological appraisal, and recommendation mapping of clinical practice guidelines for managing patients with Stevens-Johnson syndrome and toxic epidermal necrolysis

    by Mohammed AlFada, Hend Alotaibi, Sahar Alsharif, Ahmad Hecham Alani, Andrea Andrade-Miranda, Camila Montesinos Guevara, Yaolong Chen, Ruobing Lei, Jorge Acosta-Reyes, Pamela Velásquez-Salazar, et al.

    The Appraisal of Guidelines for Research and Evaluation II Instrument (AGREE II) was developed to enhance the methodological rigor of clinical practice guidelines (CPGs), aiming to generate trustworthy recommendations for various clinical scenarios. Despite its importance, there exists a gap in the quality of CPGs pertaining to Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS-TEN). The aim of the study was to evaluate SJS-TEN CPGs to shed light on areas for enhancing SJS-TEN guidelines' quality. A systematic review was conducted to identify SJS-TEN CPGs from January 2011 to December 2023 across bibliographic and guideline databases, as well as dermatology association websites. Four reviewers employed the AGREE II instrument to appraise the quality of eligible CPGs. Subsequently, AGREE II domain scores were calculated and their recommendations mapped. Seven eligible SJS-TEN CPGs reviewed, originating from Europe, North America, Asia, and an authorship Group. The highest AGREE II domain scores were observed in scope and purpose (mean: 63%, standard deviation [SD]: 23.195%) and clarity of presentation (mean: 70%, SD: 14.5%). Conversely, the lowest score was noted in the applicability domain (mean: 28%, SD: 17.44%). Only two guidelines by the British Association of Dermatologists (28.6%) met the 'recommend' level. Recommendations from all CPGs were compared in tabular form.


  • Open Access

    Isotretinoin – Induced AGEP: A Case Report

    by Hend M Alotaibi, Sultan AlNasser, Abdulelah Aldossari, Abdulrahman Alluhaybi, Reem Alsergani, Waleed Alrajban

    Acute Generalized Exanthematous Pustulosis (AGEP) is a relatively rare but severe dermatological adverse reaction characterized by the rapid onset of generalized erythema, coupled with numerous sterile nonfollicular pustules. Agents commonly implicated in triggering AGEP include antibiotics, antifungals, antimalarials, and diltiazem. We present a case of a isotretinoin induced AGEP in a young female patient known to have guttate psoriasis, inverse and scalp psoriasis. She was started on Isotretinoin as she had inflammatory acne as well. Three days later, she developed pruritic, erythematous lesions, some vesicles with a yellowish exudate over the armpits, upper chest, upper arms, and legs. A skin biopsy was performed, which, in conjunction with the clinical presentation, was suggestive of AGEP. In 2010, Filho et al described the first case of isotretinoin-induced AGEP in a female patient diagnosed with Hidradenitis Suppurativa. The EuroSCAR tool was utilized to assess the lesion morphology, clinical course, and histological outcomes, which validated the diagnosis. Using the same criteria, our patient was categorized as “definite AGEP”, further supporting the isotretinoin-induced AGEP hypothesis. This report highlights isotretinoin as a possible trigger for AGEP, emphasizing the crucial role of a thorough history and vigilant clinical assessment in early identification and management of such reactions.


  • Open Access

    Clinical Epidemiology and Phenotypic Characteristics of Hidradenitis Suppurativa Disease in the Central Region of Saudi Arabia: Findings from a Cross-Sectional

    by Hend Alotaibi, Abdulaziz Madani, Mohammed AlFada, Abdulrahman Alluhaybi, Turky Alsehli, Qais Almuhaideb, Sultan Alnasser, Abdulelah Aldossari, Maha Barakeh, Renad AlKanaan

    Background: Hidradenitis suppurativa (HS) is a complex condition that is often misdiagnosed, and regional data on its clinical features and risk factors are limited. This study aimed to explore the clinical epidemiology and phenotypic characteristics of HS in the central region of Saudi Arabia. Materials and Methods: A cross-sectional study was conducted on HS patients at King Khalid University Hospital (KKUH) in Riyadh from December 2020 to December 2021. Clinical, epidemiological, and comorbidity data were collected, and the severity of HS was categorized with the Hurley staging system. Statistical analysis was performed with SPSS, with the significance level set to p < 0.05. Results: Of the patients, 54.8% were aged 15– 30 years, 57.04% were female, and 95.56% were Saudi. Obesity was present in 48.89% of the patients, and 34.07% were smokers. The comorbid conditions included acne (10.37%), asthma (8.15%), mental disorders (2.22%), and endocrine or noncommunicable diseases (18.52%). Most patients (80.74%) had multiple affected sites. No significant associations were found between these factors and HS severity (p > 0.05). Conclusion: In conclusion, HS primarily affects young, unmarried Saudi female patients, many of whom are smokers and have comorbid conditions such as asthma and skin disorders. Clinicians should carefully assess the risk profiles of patients, particularly those with smoking habits and comorbidities, and consider screening for HS in high-risk groups.


  • The prevelance of food allergy in patients with chronic idiopathic urticaria: a systematic review and meta-analysis

    by Hend M. Alotaibi, Asail S. Alghamdi, Rahaf Tayi Almutairi, Rawan Mousa Altamimi, Raha Osailan

    Chronic idiopathic urticaria (CIU) is difficult for patients and healthcare professionals to manage owing to its chronic and unpredictable nature. While the exact cause of CIU is unknown, it is suggested that food allergies may contribute to the development of symptoms. To determine the prevalence of food allergy in patients diagnosed with CIU. This systematic review is reported in accordance with PRISMA guidelines. We included all relevant articles published from inception to April 2023 in Scopus, Midline, and Web of Science. The initial search yielded 282 articles, of which only seven were included after applying the inclusion and exclusion criteria. The systematic review included a total of 1551 patients with urticaria. Approximately 25% of patients with food allergies had CIU. The prevalence of a family history of atopy was 37.9% (range, 24.3-53.8%, P = 0.133). There was a significant risk of angioedema in patients with urticaria (P = 0.039). The risk of CIU among patients with food allergies was estimated to be one in every four patients with urticaria, with a similar risk among the adult and pediatric populations. Patients with food allergies and a history of atopy were at higher risk of CIU. Angioedema is a common concomitant manifestation associated with common urticaria. This knowledge is important to identify patients at higher risk of urticaria and implement the necessary management to minimize potential complications and maintain a controlled disease.